Inflammation & Oxidative Stress (hs-CRP, Homocysteine, GGT)

Navigation & Literature

• Parent Silo: 03 - Diagnostics & Quantified Self MOC
• Literature Dossier: Inflammation & Oxidative Stress (hs-CRP, Homocysteine, GGT) - References

---

1. Reference Range Comparison (Standard vs. Longevity Optimal)

Sub-Marker	Standard Clinical Range	Longevity / Functional Optimal	Primary Unit	Physiological Meaning
hs-CRP	$<3.0\text{ mg/L}$ ($1.0–3.0$ moderate risk)	$<0.5\text{ mg/L}$ (ideal $<0.3\text{ mg/L}$)	$\text{mg/L}$	Hepatic acute-phase reactant driven by IL-6 and IL-1$\beta$ inflammasome signaling
Homocysteine (tHcy)	$5.0–15.0\mu \text{mol/L}$	$5.0–7.0\mu \text{mol/L}$	$\mu \text{mol/L}$	One-carbon metabolism / methylation efficiency and endothelial redox marker
Gamma-Glutamyl Transferase (GGT)	$9–60\text{ U/L}$ (sex-dependent)	$10–18\text{ U/L}$ (men) / $8–14\text{ U/L}$ (women)	$\text{U/L}$	Extracellular glutathione (GSH) recycling enzyme; sensitive proxy for oxidative stress
Uric Acid	$3.5–7.2\text{ mg/dL}$	$3.5–5.0\text{ mg/dL}$	$\text{mg/dL}$	Purine catabolism & xanthine oxidase activity; intracellular pro-oxidant / eNOS inhibitor
Fibrinogen	$200–400\text{ mg/dL}$	$200–280\text{ mg/dL}$	$\text{mg/dL}$	Coagulation factor I and blood viscosity / microvascular thrombosis determinant
Myeloperoxidase (MPO)	$<470\text{ pmol/L}$	$<250\text{ pmol/L}$	$\text{pmol/L}$	Neutrophil/macrophage enzyme signifying vulnerable atherosclerotic plaque erosion
ESR (Sedimentation Rate)	$0–20\text{ mm/hr}$	$<5\text{ mm/hr}$	$\text{mm/hr}$	Non-specific erythrocyte rouleaux aggregation index of chronic systemic inflammation

---

2. Physiological Significance & Hazard Curves

Inflammaging & Vascular NLRP3 Activation (hs-CRP & MPO)

High-sensitivity C-reactive protein (hs-CRP) reflects systemic interleukin-6 (IL-6) and upstream NLRP3 inflammasome / IL-1$\beta$ activity. In the CANTOS, JUPITER, and Ridker 30-year prospective cohorts, residual inflammatory risk ($\text{hs-CRP }\ge 2.0\text{ mg/L}$) independently predicts myocardial infarction, stroke, and cardiovascular mortality even when LDL-C/ApoB are suppressed below $50–70\text{ mg/dL}$. Notably, acute viral illness or intense eccentric exercise can transiently spike hs-CRP $>5–10\text{ mg/L}$ for 48–72 hours; persistent baseline values between $1.0\text{ and }3.0\text{ mg/L}$ indicate chronic low-grade “inflammaging” driven by visceral adipokines, periodontal pathogens, or endotoxemia (see Intestinal Permeability & Zonulin). Myeloperoxidase (MPO) provides orthogonal specificity for leukocyte activation inside the arterial wall, oxidizing both LDL (to OxLDL) and HDL (rendering ApoA1 dysfunctional).

Hyperhomocysteinemia, Endothelial Dysfunction & Brain Atrophy

Homocysteine sits at the metabolic intersection of remethylation (requiring 5-MTHF + Vitamin B12 via methionine synthase, or Betaine/TMG via BHMT) and transsulfuration (requiring P5P/Vitamin B6 via cystathionine $\beta$-synthase to synthesize cysteine and glutathione). When plasma homocysteine exceeds $9–10\mu \text{mol/L}$, it accumulates asymmetric dimethylarginine (ADMA, an endogenous eNOS inhibitor), generates superoxide radicals via auto-oxidation, and promotes tau hyperphosphorylation and hippocampal gray-matter atrophy. Conversely, severely depressed homocysteine ($<4.5\mu \text{mol/L}$) can indicate excessive transsulfuration flux or glutathione/sulfite depletion.

GGT & Uric Acid as Intracellular Redox Barometers

Although clinically categorized as a hepatobiliary enzyme, GGT on cell membranes cleaves extracellular glutathione (GSH) so its constituent amino acids (especially cysteine) can be re-imported for intracellular GSH resynthesis. Consequently, GGT rises monotonically with xenobiotic exposure, hepatic steatosis, and systemic oxidative stress: individuals with GGT in the upper-normal clinical range ($30–50\text{ U/L}$) carry a $1.5\times \text{ to }2.2\times$ higher hazard of incident type 2 diabetes, heart failure, and all-cause mortality compared to those $<15\text{ U/L}$. Similarly, uric acid $>5.5\text{ mg/dL}$ reflects elevated xanthine oxidase flux (often triggered by fructose phosphorylation via fructokinase depleting hepatic ATP to AMP $\to$ uric acid), inducing mitochondrial oxidative stress and renal afferent arteriolar vasoconstriction.

---

3. Root Causes of Elevation or Depletion

• Chronic hs-CRP Elevation ($0.8–3.0\text{ mg/L}$): Visceral adipose tissue macrophage infiltration (Body Composition (DEXA, Visceral Fat)), intestinal permeability / metabolic endotoxemia (LPS translocation; Intestinal Permeability & Zonulin), obstructive sleep apnea or sleep fragmentation (Sleep Architecture), and excess Omega-6 linoleic/arachidonic acid relative to EPA/DHA.
• Elevated Homocysteine ($>8\mu \text{mol/L}$): MTHFR C677T or MTRR polymorphisms (see Methylation & Detox SNPs (MTHFR, COMT, GST)), subclinical deficiency of riboflavin (B2), pyridoxal-5’-phosphate (B6), folate (B9), or cobalamin (B12), high methionine intake without glycine/creatine buffering, or declining renal filtration (Hepatic & Renal Function (Cystatin C, eGFR)).
• Elevated GGT & Uric Acid: Alcohol consumption, non-alcoholic fatty liver disease (NAFLD/MASLD), high dietary fructose or purines, heavy metal burden, and glutathione depletion.

---

4. Actionable Interventions

Foundational Protocols (01 - Foundations)

• Autonomic & Vagal Anti-Inflammatory Tone: Activate the cholinergic anti-inflammatory pathway ($\alpha 7\text{-nAChR}$ on splenic macrophages suppressing TNF-$\alpha$/IL-6) via Vagal Tone & HRV Regulation and Breathwork Protocols.
• Visceral Fat & Glycemic Reduction: Eliminate liquid fructose/alcohol and implement Time-Restricted Feeding & Fasting plus Zone 2 & VO2 Max to clear hepatic steatosis and lower GGT and uric acid.
• Sleep Restoration: Maintain $>7.5\text{ h}$ sleep duration and high slow-wave sleep via Sleep Environment & Hygiene to prevent nocturnal IL-6 and hs-CRP surges.

Molecular & Pharmacological Interventions (02 - Compounds & Molecules)

• One-Carbon & Methylation Support: Titrate riboflavin ($25–50\text{ mg}$), 5-MTHF ($400–1000\mu \text{g}$), methylcobalamin/adenosylcobalamin, P5P ($20–50\text{ mg}$), and Trimethylglycine (TMG/Betaine $1.5–3\text{ g/day}$) per Methylation & B-Complex.
• Methylation Sparing via Creatine: Endogenous guanidinoacetate methylation to creatine consumes ~40% of total S-adenosylmethionine (SAMe); exogenous supplementation ($5\text{ g/day}$) via Creatine & Phosphocreatine System spares methyl groups and lowers homocysteine.
• Glutathione Resynthesis (GlyNAC): Restore intracellular GSH and lower GGT using N-Acetylcysteine ($1.2–2.4\text{ g/day}$) paired with Glycine ($3–5\text{ g/day}$) via Amino Acids & Precursors.
• Specialized Pro-Resolving Mediators & EPA/DHA: High-dose EPA/DHA ($2–4\text{ g/day}$) via Omega-3 & Lipid Membrane Health lowers hs-CRP and resolves vascular inflammation.

---

5. Key Scientific Evidence Summary

• Ridker et al. (2023, The Lancet & 2024, NEJM): Pooled analysis of 31,245 statin-treated patients and 30-year Women’s Health Study ($n=27,939$) proving hs-CRP is a stronger predictor of future cardiovascular mortality than LDL-C.
• Smith et al. (2010, PLoS ONE — VITACOG Trial): Demonstrated that lowering homocysteine with B-vitamins slows accelerated brain atrophy by 30–53% in mild cognitive impairment when baseline $\text{tHcy}>9.5\mu \text{mol/L}$ and Omega-3 status is adequate.
• Ruttmann et al. (2005, Circulation): Vorarlberg Health Monitoring cohort ($n=163,944$) establishing dose-dependent cardiovascular mortality hazard ratios across upper-normal GGT quartiles.

See full bibliographic details and quantitative effect sizes in Inflammation & Oxidative Stress (hs-CRP, Homocysteine, GGT) - References.